摘要
目的观察心痛方对冠心病合并颈动脉斑块患者P选择素(PS)、P选择素糖蛋白配体-1(PSGL-1)、血小板-白细胞聚集体(PLA)、血小板单核细胞聚集体(PMA)的影响,探讨心痛方临床疗效的作用机制。方法将60例患者随机分为心痛方组和对照组,每组30例。心痛方组服用心痛方,对照组服用拜阿司匹林、阿托伐他汀钙,疗程均为2个月。采用流式细胞术检测治疗前后患者PS、PSGL-1、PLA、PMA的表达量。结果心痛方与对照药物均能明显抑制PS、PSGL-1、PLA、PMA的表达(P<0.01),治疗组对PLA、PMA的影响优于对照组(P<0.05)。结论心痛方对PS、PSGL-1、PLA、PMA的表达有明显抑制作用,说明心痛方能通过抑制血小板-白细胞相互反应,减少冠心病合并颈动脉斑块患者的炎症反应。
Objective To observe the intervention effects of Xintongfang on the expression of P-selectin （PS）, P-selectin glycoprotein ligand-1 （PSGL-1）, platelet-leukocyte aggregates （PLA） and platelet-monocyte aggregates （PMA） in patients of coronary heart disease with carotid artery plaque. Methods Sixty patients were randomly divided into Xintongfang group and the control group, with 30 cases in each group. Xintongfang group was given Xintongfang, the control group was given aspirin and atorvastatin calcium for two months. The expression of PS, PSGL-1, PLA and PMA were tested by flow cytometry before and after treatment. Results The expression of PS, PSGL-1, PLA and PMA in two groups were reduced （P 〈 0.01）. Xintongfang group had more obvious effects on the expression of PLA and PMA than the control group （P〈0.05）. Conclusion Xintongfang can reduce the degree of inflammatory in patients of coronary heart disease with carotid artery plaque by inhibiting platelet-leukocyte interaction.
出处
《中国中医药信息杂志》
CAS
CSCD
2014年第1期19-21,共3页
Chinese Journal of Information on Traditional Chinese Medicine
基金
湖南省教育厅重点项目(11A085)
